The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients

High Clinical Response Rate of S ézary Syndrome to Immunomodulatory Therapies

(2011) Brian A. Raphael   ARCHIVES OF DERMATOLOGY

Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma

(2011) Maria Wysocka et al.   LEUKEMIA & LYMPHOMA

Histone deacetylases as regulators of inflammation and immunity

(2011) Melanie R. Shakespear et al.   TRENDS IN IMMUNOLOGY

Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection

(2010) T. Roger et al.   BLOOD

Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs

(2010) Tatiana Akimova et al.   CLINICAL IMMUNOLOGY

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells

(2010) W Song et al.   LEUKEMIA

Chemical phylogenetics of histone deacetylases

(2010) James E Bradner et al.   Nature Chemical Biology

Vorinostat for the Treatment of Bullous Pemphigoid in the Setting of Advanced, Refractory Cutaneous T-Cell Lymphoma

(2009) Jennifer M. Gardner   ARCHIVES OF DERMATOLOGY

Development of vorinostat: Current applications and future perspectives for cancer therapy

(2009) Victoria M. Richon et al.   CANCER LETTERS

A phosphorylation-acetylation switch regulates STAT1 signaling

(2009) O. H. Kramer et al.   GENES & DEVELOPMENT

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

(2009) D. Ritchie et al.   HAEMATOLOGICA

Using histone deacetylase inhibitors to enhance Foxp3+ regulatory T-cell function and induce allograft tolerance

(2009) Liqing Wang et al.   IMMUNOLOGY AND CELL BIOLOGY

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome

(2009) Jennifer M. Gardner et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

(2008) Alejandro Villagra et al.   NATURE IMMUNOLOGY

HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen

(2008) N. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA